These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17931089)

  • 1. Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: a review.
    Rasu RS; Crawford T; Manley HJ; Balkrishnan R
    Expert Opin Pharmacother; 2007 Oct; 8(15):2543-51. PubMed ID: 17931089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication considerations for patients with chronic kidney disease who are not yet on dialysis.
    Liles AM
    Nephrol Nurs J; 2011; 38(3):263-70. PubMed ID: 21877459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication regimen complexity in patients with uncontrolled hypertension and/or diabetes.
    Rettig SM; Wood Y; Hirsch JD
    J Am Pharm Assoc (2003); 2013; 53(4):427-31. PubMed ID: 23892818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a value-based formulary in three chronic disease cohorts.
    Yeung K; Basu A; Marcum ZA; Watkins JB; Sullivan SD
    Am J Manag Care; 2017 Mar; 23(3 Suppl):S46-S53. PubMed ID: 29648740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term medication cost savings for treating hypertension and diabetes after gastric bypass.
    Ghiassi S; Morton J; Bellatorre N; Eisenberg D
    Surg Obes Relat Dis; 2012; 8(3):269-74. PubMed ID: 21723203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential savings without compromising the quality of care.
    Norman C; Zarrinkoub R; Hasselström J; Godman B; Granath F; Wettermark B
    Int J Clin Pract; 2009 Sep; 63(9):1320-6. PubMed ID: 19691615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending.
    Musich S; Wang S; Hawkins K
    Popul Health Manag; 2015 Jun; 18(3):151-8. PubMed ID: 25247449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications.
    Maciejewski ML; Bryson CL; Perkins M; Blough DK; Cunningham FE; Fortney JC; Krein SL; Stroupe KT; Sharp ND; Liu CF
    Am J Manag Care; 2010 Jan; 16(1):e20-34. PubMed ID: 20059288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB; Kranjcević K; Reiner Z; Blazeković SM; Spehar SS
    Croat Med J; 2005 Dec; 46(6):984-9. PubMed ID: 16342354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of illness of hypertension and comorbid diabetes.
    Eaddy MT; Shah M; Lunacsek O; Stanford RH
    Curr Med Res Opin; 2008 Sep; 24(9):2501-7. PubMed ID: 18671895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The double burden of disease and the challenge of health access: Evidence from Access, Bottlenecks, Cost and Equity facility survey in Ghana.
    Kushitor MK; Boatemaa S
    PLoS One; 2018; 13(3):e0194677. PubMed ID: 29570720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy in the heart transplant recipient: Part III: common medical problems.
    Lindenfeld J; Page RL; Zolty R; Shakar SF; Levi M; Lowes B; Wolfel EE; Miller GG
    Circulation; 2005 Jan; 111(1):113-7. PubMed ID: 15630040
    [No Abstract]   [Full Text] [Related]  

  • 14. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
    Hogan TJ; Elliott WJ; Seto AH; Bakris GL
    Pharmacoeconomics; 2002; 20(1):37-47. PubMed ID: 11817991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of diabetes in patients with chronic kidney disease.
    Ahmed Z; Simon B; Choudhury D
    Postgrad Med; 2009 May; 121(3):52-60. PubMed ID: 19491540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study.
    Heinze G; Hronsky M; Reichardt B; Baumgärtel C; Müllner M; Bucsics A; Winkelmayer WC
    Appl Health Econ Health Policy; 2015 Apr; 13(2):193-205. PubMed ID: 25536928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of pay for performance on the control of blood pressure in people with chronic kidney disease stage 3-5.
    Karunaratne K; Stevens P; Irving J; Hobbs H; Kilbride H; Kingston R; Farmer C
    Nephrol Dial Transplant; 2013 Aug; 28(8):2107-16. PubMed ID: 23658247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.